BRIDGEWATER, N.J., Oct. 2, 2012 /PRNewswire/ -- Kinerase, a sub-brand of Valeant Pharmaceuticals North America, is pleased to announce their partnership with the American Breast Cancer Foundation for the month of October. The brand will be donating 20 percent of the proceeds from their two new anti-aging products, Advanced Cream and Advanced Lotion, when purchased at Ulta, the premium beauty retailer, between October 1 and October 31, 2012.
New to the line, Kinerase Advanced Lotion and Cream both moisturize skin while supporting its natural production of hyaluronic acid. Along with visible improvement in the appearance of fine lines and wrinkles, skin is smoother and more hydrated, with a more even tone.
"We are so proud to partner with the American Breast Cancer Foundation," said Alissa Lynch, VP & General Manager Valeant Pharmaceuticals. "By donating a portion of the sales from our in-demand new products, Kinerase Advanced Cream and Lotion, we hope to not only increase brand awareness but make a difference in the fight against breast cancer."
The American Breast Cancer Foundation (ABCF) provides screenings, diagnostic testing and treatment services to individuals and medical clinics either at a reduced fee or free of charge nationwide. Over 50 percent of those who receive assistance from the foundation are already diagnosed with breast cancer. Partnering with the ABCF provides the opportunity for both Kinerase and customer to advance the foundation's mission of financial assistance to these patients.
To participate in the donation program, purchase Kinerase® Advanced Lotion and Advanced Cream at Ulta from October 1 – 31, 2012.
ABOUT VALEANT PHARMACEUTICALS:
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant has over 20 years of experience in dermatological science. More information about Valeant can be found at www.valeant.com.
SOURCE Valeant Pharmaceuticals International, Inc.